Skip to main content
Premium Trial:

Request an Annual Quote

Funding Update: NSF Grants Awarded to University of Nebraska and More

Premium

Recent NSF Awards in Proteomics and Protein Research

Title: The Influence of Soil Attachment on the Biologic Activity of Extracellular Proteins
Principal Investigator: Shannon Bartelt-Hunt
Sponsor: University of Nebraska-Lincoln
Start/End Date: Sept. 1, 2012 – Aug. 31, 2017
Amount Awarded to Date: $413,883

Funds a study using a new analytical tool for measuring the amounts and quantities of proteins adsorbed to surfaces for the purpose of evaluating the interaction of extracellular proteins with environmentally relevant surfaces and how this interaction changes protein function.


Title: The Role of Protein Acetylation in Stress Responses and in Setting Tolerance Limits in Differently Adapted Mussels (Genus Mytilus): A Comparative Proteomics Approach
Principal Investigator: Lars Tomanek
Sponsor: California Polytechnic State University Foundation
Start/End Date: Feb. 15, 2012 – Jan. 31, 2015
Amount Awarded to Date: $183,888

Funds an effort to identify changes in the marine mussel proteome in response to environmental stresses. In addition to changes in protein abundance, the research will focus on protein post-translational modifications, in particular sirtuin-induced deacetylation.


Title: Exploring Unknown Diversity of Short Peptide Neurotoxins and Prey Targets of Provisioning Spider Wasps (Pompilidae) of New Mexico
Principal Investigator: Manda Jost
Sponsor: Western New Mexico University
Start/End Date: Feb. 15, 2012 – Jan. 31, 2015
Amount Awarded to Date: $121,919

Funds a study characterizing venom peptides from a range of spider wasp samples using a variety of techniques including mass spectrometry in order to address questions of evolutionary history.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.